Ischemic stroke after radiofrequency catheter ablation (RFCA) in atrial fibrillation (AF) patients is a great challenge for electrophysiologists. We performed this retrospective study to evaluate clinical and echocardiographic characteristics associated with increased risk of ischemic stroke following RFCA. A total of 2,352 consecutive patients with AF who underwent first-time RFCA were analyzed. Among 10,023 patient*year follow up, ischemic stroke occurred in 49 patients (0.49% per year). Late recurrence after last RFCA was significantly associated with ischemic stroke (3.8% vs. 12.9%, p < 0.001). Old age (≥60 years old) (3.2% vs. 15.4%, p = 0.001), non-paroxysmal AF (hazard ratio = 1.91, p = 0.024), left atrium (LA) size ≥45.0 mm (6.6% vs. 11.7%, p < 0.001), E over E' ≥10 (4.3% vs. 20.1%, p < 0.001), dense spontaneous echo contrast (SEC) (5.2% vs. 19.0%, p = 0.006), and decreased left atrial appendage (LAA) flow velocity (≤40 cm/sec) (4.1% vs. 10.8%, p < 0.001) were also associated with increased risk of ischemic stroke. The REVEEAL score derived from the risk factors identified in this study was superior to CHA 2 Ds 2 -VASc score (p < 0.001) for the prediction of ischemic stroke. In conclusion, the risk factors for ischemic stroke in post-RFCA AF patients are not identical to RFCA naive AF patients and different approach to stratify the risk of ischemic stroke is needed.
Definitions. In the current study, ischemic stroke was defined as any neurological symptoms lasting more than 24 hours which cannot be explained by other medical conditions. Transient ischemic attack was defined as any neurologic symptoms that were resolved completely within 24 hours which are not attributable to any other medical causes. If acute infarction lesion was observed in brain computed tomography or magnetic resonance imaging, the event was classified as ischemic stroke despite complete restoration of neurologic symptoms. Hemorrhagic stroke was defined as any neurologic symptoms accompanied by hemorrhagic lesions in brain computed tomography or magnetic resonance imaging. All patients who experienced stroke were evaluated by neurologist or neurosurgeon and future treatment strategy was determined based on collaboration among cardiologist, neurologist, and neurosurgeon. Late recurrence was defined as any atrial tachyarrhythmia lasting for more than 30 seconds occurring after 3 months of blanking period after RFCA.
Anticoagulation. In the current study, prescription of anticoagulants was recorded in every patient throughout the total follow up period. Anticoagulants consisted of warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban. We calculated anticoagulated follow up duration and non-anticoagulated follow up duration for each patient. Therefore, we were able to obtain anticoagulation coverage, which is defined as (anticoagulated duration/ total follow up duration)*100%, for each individual patient and for any specific group.
Statistics. Continuous variables are described as means ± standard deviations. Categorical variables are presented as percentile values. Continuous variables were compared with Student t test. Categorical variables were compared with chi-square test or Fisher's exact test as appropriate. Cumulative incidence of stroke (time to first event) was depicted by Kaplan-Meier survival curve analysis and difference between groups were compared using log-rank test. Cox regression analysis was performed to calculate univariate hazard ratio (HR) and HR adjusted for individual components of CHA 2 DS 2 -VASc score. Receiver operating characteristic (ROC) curve analysis with calculation of area under curve (AUC) was performed to evaluate efficacy of CHA 2 DS 2 -VASc score and new scoring systems developed in this study to predict future risk of ischemic stroke in AF patients undergoing first-time RFCA. Comparison of two ROC curves was performed by statistical method suggested by Hanley and McNeil 14 . Missing data were excluded from each analysis and no imputation was performed. All significance tests were two-tailed and p value ≤ 0.05 were considered statistically significant. All statistical analyses were performed with SPSS version 21.0 (IBM, Armonk, NY, USA).
Results
Patients. Between June 1998 and June 2016, a total of 2,352 patients underwent first-time RFCA for AF. Total number of procedure was 2,997 with 546 re-do procedures and 83 tri-do procedures. A total of 2,293 (97.5%) and 2,135 (90.8%) patients underwent TTE and TEE evaluation, respectively. Baseline characteristics of the study population are summarized in Supplementary Table S1 . Briefly, mean age was 55.4 ± 10.9 and 79.6% of patients were male. AF was non-paroxysmal in 40.2% of patients and mean LA size was 41.1 mm. Mean CHA 2 DS 2 -VASc score was 1.3 ± 1.3. Total follow up duration was 10,023 patient*years and 1 year follow-up rate was 83.6%. During follow up, a total of 82 all strokes occurred with annualized incidence of 0.82%. Ischemic stroke occurred in 49 patients with annualized incidence of 0.49% and transient ischemic attack in 13 patients ( Supplementary  Fig. S1 ). The location and severity of ischemic stroke in 49 patients are summarized in Supplementary Table S2 .
Risk factors for ischemic stroke. Baseline clinical and echocardiographic characteristics were compared between patients with and without ischemic stroke after RFCA (Table 1 ). Patients who experienced ischemic stroke after RFCA had significantly older age, larger LA, higher mean CHA 2 DS 2 -VASc score, unfavorable diastolic function profile, decreased LAA flow velocity, and higher prevalence of non-paroxysmal AF and SEC as compared with patients who did not suffer ischemic stroke.
Patient who experienced late recurrence after last RFCA showed significantly higher cumulative incidence (3.8% vs. 12.9%, log-rank p < 0.001; Fig. 1a ) and annualized incidence (0.28% vs. 0.91%) of ischemic stroke as compared with patients who maintained sinus rhythm throughout the whole follow up period despite higher anticoagulation coverage (15.2% vs. 31.8%). HR adjusted for individual components of CHA 2 DS 2 -VASc score was 3.08 (p < 0.001). Late recurrence after last RFCA was associated with higher risk of future ischemic stroke irrespective of whether CHA 2 DS 2 -VASc score was <2 or ≥2 (p for interaction = 0.352; Fig. 1b ). Among 1,529 patients with CHA 2 DS 2 -VASc score <2, 27 patients experienced ischemic stroke after RFCA. Clinical and echocardiographic characteristics of these 27 patients who suffered ischemic stroke despite low CHA 2 DS 2 -VASc score are summarized in Supplementary Table S3 www.nature.com/scientificreports www.nature.com/scientificreports/ showed significantly higher risk of ischemic stroke compared to patients with CHA 2 DS 2 -VASc ≥2 without late recurrence (5.9% vs. 12.9%, log-rank p = 0.011; Supplementary Fig. S2 ). Patients over 60 years old experienced significantly higher risk of ischemic stroke (3.2% vs. 15.4%, log-rank p = 0.001; annualized incidence = 0.32% vs. 0.78%; adjusted HR = 2.76, p = 0.001; Fig. 1c ) despite higher anticoagulation coverage as compared to patients under 60 years old (17.0% vs. 27.5%). Non-paroxysmal AF (HR = 1.91, p = 0.024; annual incidence = 0.37% vs. 0.69%; adjusted HR = 1.81, p = 0.038; Fig. 1d ) was also associated with increased risk of ischemic stroke despite higher anticoagulation coverage (13.0% vs. 33.2%).
TTE findings were substantially important to predict future risk of ischemic stroke. Patients with LA size over 45.0 mm had a significantly increased risk of ischemic stroke following RFCA (6.6% vs. 11.7%; log-rank p < 0.001; annualized incidence = 0.35% vs. 0.91%; adjusted HR = 2.22, p = 0.008; Fig. 2a ). E over E' ≥10 was also associated with substantially higher risk of ischemic stroke (4.3% vs. 20.1%; log-rank p < 0.001; annualized incidence = 0.20% vs. 0.88%; adjusted HR = 3.65, p = 0.002; Fig. 2b ). Presence of dense SEC (5.2% vs. 19.0%; log-rank p = 0.006; annualized incidence = 0.40% vs. 1.41%; adjusted HR = 3.18, p = 0.024; Fig. 3a ) and decreased left atrial appendage flow velocity (≤40 cm/sec) (4.1% vs. 10.8%, log-rank p < 0.001; annualized incidence = 0.23% vs. 0.88%; adjusted HR = 3.55, p < 0.001; Fig. 3b ) in TEE were also important predictors of ischemic stroke in AF patients undergoing RFCA. Anticoagulation coverage was higher in patients with aforementioned unfavorable TTE and TEE findings but these patients experienced higher risk of ischemic stroke following RFCA (Figs 2 and 3) .
Our analyses revealed that aforementioned risk factors for ischemic stroke were also significant risk factors for ischemic stroke plus TIA. HR and HR adjusted for individual components of CHA 2 DS 2 -VASc score of each risk factor are summarized in Supplementary Table S4 . www.nature.com/scientificreports www.nature.com/scientificreports/ REVEEAL and REAL score. In the current study, CHA 2 DS 2 -VASc score was not a risk factor for post-RFCA ischemic stroke (HR = 1.22, p = 0.487; Supplementary Fig. S3 ). Furthermore, CHA 2 DS 2 -VASc score was not able to predict future risk of ischemic stroke in ROC curve analysis (AUC = 0.557, p = 0.169). We created a new scoring system named REVEEAL score based on the presence of late recurrence, old age (≥60 years old), type of AF, LA size, E over E' , dense SEC, and decreased LAA flow velocity (≤40 cm/sec) ( Fig. 4a ) and REAL score based on the presence of late recurrence, old age, and type of AF (Fig. 4b) . In contrast to CHA 2 DS 2 -VASc score, REVEEAL (AUC = 0.783, p < 0.001; Fig. 4a ) and REAL (AUC = 0.751, p < 0.001; Fig. 4b ) scoring systems were able to predict future risk of ischemic stroke. Comparison of two ROC curves revealed that REVEEAL and REAL scoring systems were superior to CHA 2 DS 2 -VASc system (p < 0.001 for both). Significantly different risk of ischemic stroke was observed among tertiles of REVEEAL (HR = 5.48, p < 0.001; Fig. 4c ) and REAL (HR = 2.99, p < 0.001; Fig. 4d ) score with higher incidence of ischemic stroke in high tertile group despite higher anticoagulation coverage. Direct comparison of REVEEAL and REAL scoring systems showed statistical tendency for better prediction of ischemic stroke when TTE and TEE findings were added to clinical parameters (AUC = 0.783 vs. 0.714, p = 0.069; Supplementary Fig. S4 ). www.nature.com/scientificreports www.nature.com/scientificreports/
Discussion
The primary findings of the current study can be summarized as follows: (i) the incidence of ischemic stroke after RFCA was 0.49% per year with a mean CHA 2 DS 2 -VASc score of 1.3; (ii) in this registry of post-RFCA AF patients, CHA 2 DS 2 -VASc score did not predict future risk of ischemic stroke; (iii) the clinical and echocardiographic risk factors for ischemic stroke was the presence of late recurrence, old age, type of AF, LA size, E over E' , dense SEC, and decreased LAA flow velocity; (iv) in contrast to CHA 2 DS 2 -VASc score, REVEEAL and REAL scoring systems were able to predict future risk of ischemic stroke. The strong point of the current study can be summarized as follows: (i) prescription history of anticoagulants was extensively reviewed for all patients and for total follow up duration. Therefore, we were able to calculate mean anticoagulation coverage for individual patients and for specific group; (ii) all consecutive patients in our institution were included in the analysis to minimize any potential bias; (iii) TEE was performed in more than 90% of patients. Therefore, we were able to integrate not only TTE but also TEE findings to conventional clinical parameters. AF, RFCA, and ischemic stroke. There are 2 major theories explaining the association between AF and ischemic stroke: rhythm and substrate 15 . In atrial rhythm theory, increased risk of ischemic stroke is the result of blood stasis in LA and LAA which is caused by AF. Decreased flow velocity in LA or LAA is associated with development of SEC in which thrombus formation and embolization are likely to occur 11, [16] [17] [18] [19] . Substrate theory focuses on the inability of rhythm control therapy, although strongly challenged by recent studies, to reduce ischemic stroke and lack of temporal association between paroxysmal AF and ischemic stroke in prolonged rhythm monitoring 15, 20 . It is suggested that not only blood stasis but also atrial remodeling leading to fibrotic and prothrombotic atrial cardiomyopathy plays a significant role 15 . Irrespective of underlying mechanism, anticoagulation with warfarin or NOACs is associated with significant reduction of ischemic stroke 21, 22 . However, whether RFCA is associated with a reduction of ischemic stroke is under active debate. Previous studies suggested that RFCA do not reduce the risk of ischemic stroke 23 . However, recent studies report a significant reduction in the risk of ischemic stroke in AF patients undergoing RFCA 7, 8, 24 . Friberg et al. demonstrated in their propensity score matched analysis that AF patients undergoing RFCA experienced a 31% reduction in ischemic stroke and the beneficial effect of RFCA was most dominant in patients with CHA 2 DS 2 -VASc score ≥2 with a 61% risk reduction 7 . Karasoy and his colleagues also showed that RFCA is associated with a 47% risk reduction of ischemic stroke in multivariate adjusted retrospective analysis 8 . However, there is no randomized clinical trials demonstrating superiority of RFCA over medical therapy in terms of preventing ischemic stroke and further data are needed for definitive conclusion.
Risk factors for ischemic stroke after RFCA. The incidence of ischemic stroke in AF patients undergoing RFCA merits further attention. Annualized incidence of ischemic stroke in the studies performed by Friberg et al. and Karasoy et al. was 0.70% and 0.55% respectively 7, 8 . Annualized incidence of ischemic stroke in the current study, which was 0.49%, is also similar with previous studies. Collectively, incidence of ischemic stroke after RFCA is not high and therefore, anticoagulation treatment in these post-RFCA AF patients deserves in-depth discussion. In this analysis, patients without late recurrence showed 0.28% annualized incidence of ischemic stroke which is far below the threshold for both warfarin and NOAC treatment suggested by previous study 10 . Anticoagulation coverage in the group was 15.2% and considering mandatory anticoagulation duration of 2 months after RFCA, anticoagulation was rarely prescribed. Therefore, the risk of ischemic stroke in patients without late recurrence was indeed low. Furthermore, annualized incidence of ischemic stroke in patients with CHA 2 DS 2 -VASc score ≥2 but without late recurrence was significantly low as compared to patients with CHA 2 DS 2 -VASc score <2 and who experienced late recurrence ( Supplementary Fig. S2 ). The risk of ischemic stroke in patients with CHA 2 DS 2 -VASc score ≥2 but without late recurrence should be revisited. CHA 2 DS 2 -VASc scoring system is a well proven risk predictor of ischemic stroke in AF patients 1 . However, the efficacy of CHA 2 DS 2 -VASc score in AF patients undergoing RFCA is not well validated. Previous studies suggest that CHADS 2 and CHA 2 DS 2 -VASc scoring systems are not ideal to guide anticoagulation treatment in post-RFCA AF patients 8, 9 . CHA 2 DS 2 -VASc scoring system also did not predict the risk of ischemic stroke in our registry with AUC near 0.5. The reason for this discrepancy is not clear. Substantial number of AF patients, especially those with paroxysmal AF, remain in sinus rhythm after RFCA and despite late recurrence, RFCA is usually associated with significant reduction in overall AF burden 25, 26 , and AF burden is associated with risk of ischemic stroke 27 . Because CHA 2 DS 2 -VASc score was originally developed to predict the risk of ischemic stroke in ' AF' patients, the substantial reduction of AF burden after RFCA might have significant influence on the predictive value of CHA 2 DS 2 -VASc score. Low number of ischemic stroke events in patients undergoing RFCA might also affect the predictive value of CHA 2 DS 2 -VASc score. REVEEAL and REAL scores, in contrast to CHA 2 DS 2 -VASc score, were able to predict future risk of ischemic stroke in the current study with AUC over 0.7. Low tertile group of REVEEAL and REAL score represented patients with significantly low risk of ischemic stroke with 0.00% and 0.14% annualized incidence for low tertile of REVEEAL and REAL respectively. Mid and higher tertile groups of each scoring system showed significantly higher risk of ischemic stroke despite substantially higher anticoagulation coverage. The predictive value of REVEEAL and REAL scoring systems in external validation cohort should be performed and risk-benefit of anticoagulation in these low risk patients needs further investigation. TEE findings and ischemic stroke. The association between ischemic stroke and TEE parameters such as SEC or LAA flow velocity in AF patients is documented in previous studies 16, 17 . However, clinical implication of TEE findings in post-RFCA AF patients is not fully evaluated. Our data suggest that dense SEC and decreased LAA flow velocity are significantly associated with future risk of ischemic stroke in AF patients undergoing RFCA. In patients who remain in AF despite RFCA, it is likely that TEE parameters will apply as identical to AF patients without history of RFCA. Even in patients with successful restoration of sinus rhythm through RFCA, www.nature.com/scientificreports www.nature.com/scientificreports/ whether decreased functional status of LA and LAA, especially in non-paroxysmal AF patients, will recover after successful ablation remains uncertain. Therefore, potential risk of ischemic stroke should be kept in mind irrespective of the results of RFCA in patients with unfavorable findings in baseline TEE evaluation.
Limitations.
We acknowledge that the current study has several shortcomings. First, this was a retrospective analysis and therefore, is not free from intrinsic limitations of retrospective analysis. Second, the number of ischemic stroke was not large which is a universal problem encountered in all studies analyzing RFCA. Incidence of ischemic stroke in post RFCA patients is far below 1%, a consistent finding observed in many studies including the current data. Third, our registry was exclusively consisted of East Asian patients and therefore, care should be taken when expanding our results to other ethnic groups. Fourth, there can be a potential selection bias between those who did and did not undergo TEE evaluation. However, substantial number of patients had TEE evaluation (90.8%) and whether to perform or not perform TEE evaluation was based on patient preference and tolerance to swallow the probe rather than medical condition such as previous history of stroke or type of AF. Fifth, although the total follow-up duration was sufficient (10,023 patient*years), the duration of the follow-up was not uniform for individual patients.
